Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,inventory,accountsPayable,longTermInvestments,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,changeToNetincome,capitalExpenditures,otherCashflowsFromInvestingActivities,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,marketState,currency,exchange,shortName,market,priceHint,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,epsCurrentYear,exchangeDataDelayedBy,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jun 29, 2021) 4","Short Ratio (Jun 29, 2021) 4","Short % of Float (Jun 29, 2021) 4","Short % of Shares Outstanding (Jun 29, 2021) 4","Shares Short (prior month May 27, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry
t0,DCPH,503013000.0,57964500,55681000,,-61298000,,-61298000,30747000,-30747000,-61494000,-61494000,,,,,,0,25156000,86650000,55903000,196000,,-61298000,-61298000,1318157000.0,92233000.0,503013000.0,5482000.0,595246000.0,579000.0,-815766000.0,43000.0,3102000.0,201648000.0,63789000.0,43000.0,45512000.0,546632000.0,300527000.0,21821000.0,7090000.0,11905000.0,,124545000.0,-433000.0,123908000.0,9524000.0,-13048000.0,9524000.0,65751000.0,1000.0,-67682000.0,732000.0,1973000.0,-7925000.0,12317000.0,-637000.0,,,482843000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,REGULAR,USD,NMS,"Deciphera Pharmaceuticals, Inc.",us_market,2,NasdaqGS,"Deciphera Pharmaceuticals, Inc.",USD,357618,386216,5.8999977,0.22519074,26.2 - 68.4,-36.300003,-0.5307018,26.2,68.4,1620145320,1635937140,1636372800,-4.487,-3.21,-4.86,0,-6.6049376,8.687,30.958889,1.1411095,0.036858864,37.750614,-5.6506157,-0.14968275,1860660352,-9.999999,3.6951764,15,America/New_York,EDT,-14400000,False,False,1.904757,31.21 - 32.1,31.5,30.88,31.9,9,10,finmb_8221694,32.1,1630503682,0.5999985,31.78,32.1,31.21,301473,1.51,,,68.4,26.2,30.96,37.75,357.62k,386.22k,57.96M,,36.66M,29.42%,76.82%,3.13M,7.23,7.62%,5.40%,3.27M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-383.18%,-24.23%,-43.39%,67.18M,1.18,"40,474.20%",-157.11M,-254.84M,-254.98M,-4.49,,502.18M,8.66,30.98M,6.16,8.57,8.69,-227M,-137.13M,Value,02451,Healthcare,350,9,7,"Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing immunokinase inhibitors comprising vimseltinib (DCC-3014) that is in Phase 1b/2 clinical trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase 1b/2 clinical trial to treat metastatic solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, it is developing DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. The company serves in the United States and Europe. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.",Waltham,781 209 6400,MA,8,1609372800,1625097600,8,United States,http://www.deciphera.com,86400,8,200 Smith Street,785 830 2150,Biotechnology
t-1,DCPH,543676000.0,57964500,55681000,,-62740000,,-62740000,30070000,-32929000,-62999000,-62999000,,,,,,0,19486000,82485000,52415000,259000,,-62740000,-62740000,1297557000.0,98756000.0,543676000.0,3407000.0,642432000.0,576000.0,-754468000.0,11000.0,3102000.0,135897000.0,69992000.0,11000.0,45924000.0,584031000.0,416033000.0,13896000.0,5716000.0,12308000.0,9375000.0,47486000.0,2375000.0,46079000.0,27792000.0,2579000.0,27955000.0,24743000.0,1000.0,-49128000.0,695000.0,-786000.0,-2082000.0,10831000.0,-430000.0,-977000.0,-163000.0,514039000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,REGULAR,USD,NMS,"Deciphera Pharmaceuticals, Inc.",us_market,2,NasdaqGS,"Deciphera Pharmaceuticals, Inc.",USD,357618,386216,5.8999977,0.22519074,26.2 - 68.4,-36.300003,-0.5307018,26.2,68.4,1620145320,1635937140,1636372800,-4.487,-3.21,-4.86,0,-6.6049376,8.687,30.958889,1.1411095,0.036858864,37.750614,-5.6506157,-0.14968275,1860660352,-9.999999,3.6951764,15,America/New_York,EDT,-14400000,False,False,1.904757,31.21 - 32.1,31.5,30.88,31.9,9,10,finmb_8221694,32.1,1630503682,0.5999985,31.78,32.1,31.21,301473,1.51,,,68.4,26.2,30.96,37.75,357.62k,386.22k,57.96M,,36.66M,29.42%,76.82%,3.13M,7.23,7.62%,5.40%,3.27M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-383.18%,-24.23%,-43.39%,67.18M,1.18,"40,474.20%",-157.11M,-254.84M,-254.98M,-4.49,,502.18M,8.66,30.98M,6.16,8.57,8.69,-227M,-137.13M,Value,02451,Healthcare,350,9,7,"Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing immunokinase inhibitors comprising vimseltinib (DCC-3014) that is in Phase 1b/2 clinical trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase 1b/2 clinical trial to treat metastatic solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, it is developing DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. The company serves in the United States and Europe. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.",Waltham,781 209 6400,MA,8,1609372800,1625097600,8,United States,http://www.deciphera.com,86400,8,200 Smith Street,785 830 2150,Biotechnology
t-2,DCPH,569086000.0,57964500,55681000,,-63701000,,-63701000,30143000,-33854000,-63997000,-63997000,,,,,,0,15449000,79446000,49303000,296000,,-63701000,-63701000,1260209000.0,90582000.0,569086000.0,1623000.0,659668000.0,566000.0,-691728000.0,39000.0,2125000.0,111154000.0,61188000.0,39000.0,47096000.0,571458000.0,434171000.0,11814000.0,4596000.0,10237000.0,38989000.0,3047000.0,-2852000.0,1821000.0,3228000.0,11766000.0,3228000.0,-44292000.0,1000.0,-49341000.0,666000.0,-1657000.0,-4430000.0,10867000.0,-1233000.0,-977000.0,-163000.0,510270000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,REGULAR,USD,NMS,"Deciphera Pharmaceuticals, Inc.",us_market,2,NasdaqGS,"Deciphera Pharmaceuticals, Inc.",USD,357618,386216,5.8999977,0.22519074,26.2 - 68.4,-36.300003,-0.5307018,26.2,68.4,1620145320,1635937140,1636372800,-4.487,-3.21,-4.86,0,-6.6049376,8.687,30.958889,1.1411095,0.036858864,37.750614,-5.6506157,-0.14968275,1860660352,-9.999999,3.6951764,15,America/New_York,EDT,-14400000,False,False,1.904757,31.21 - 32.1,31.5,30.88,31.9,9,10,finmb_8221694,32.1,1630503682,0.5999985,31.78,32.1,31.21,301473,1.51,,,68.4,26.2,30.96,37.75,357.62k,386.22k,57.96M,,36.66M,29.42%,76.82%,3.13M,7.23,7.62%,5.40%,3.27M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-383.18%,-24.23%,-43.39%,67.18M,1.18,"40,474.20%",-157.11M,-254.84M,-254.98M,-4.49,,502.18M,8.66,30.98M,6.16,8.57,8.69,-227M,-137.13M,Value,02451,Healthcare,350,9,7,"Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing immunokinase inhibitors comprising vimseltinib (DCC-3014) that is in Phase 1b/2 clinical trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase 1b/2 clinical trial to treat metastatic solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, it is developing DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. The company serves in the United States and Europe. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.",Waltham,781 209 6400,MA,8,1609372800,1625097600,8,United States,http://www.deciphera.com,86400,8,200 Smith Street,785 830 2150,Biotechnology
t-3,DCPH,619684000.0,57964500,55681000,,-67241000,,-67241000,29933000,-38999000,-68932000,-68932000,,,,,,0,7090000,76022000,46089000,1691000,,-67241000,-67241000,1247158000.0,66621000.0,619684000.0,1027000.0,686305000.0,561000.0,-628027000.0,-8000.0,2125000.0,155446000.0,51339000.0,-8000.0,29663000.0,633086000.0,454890000.0,7384000.0,1389000.0,12582000.0,21431000.0,-14766000.0,1455000.0,-17751000.0,4389000.0,1447000.0,4689000.0,-74206000.0,1000.0,-60844000.0,484000.0,-798000.0,-7384000.0,11193000.0,-2984000.0,-1000.0,-300000.0,581747000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,REGULAR,USD,NMS,"Deciphera Pharmaceuticals, Inc.",us_market,2,NasdaqGS,"Deciphera Pharmaceuticals, Inc.",USD,357618,386216,5.8999977,0.22519074,26.2 - 68.4,-36.300003,-0.5307018,26.2,68.4,1620145320,1635937140,1636372800,-4.487,-3.21,-4.86,0,-6.6049376,8.687,30.958889,1.1411095,0.036858864,37.750614,-5.6506157,-0.14968275,1860660352,-9.999999,3.6951764,15,America/New_York,EDT,-14400000,False,False,1.904757,31.21 - 32.1,31.5,30.88,31.9,9,10,finmb_8221694,32.1,1630503682,0.5999985,31.78,32.1,31.21,301473,1.51,,,68.4,26.2,30.96,37.75,357.62k,386.22k,57.96M,,36.66M,29.42%,76.82%,3.13M,7.23,7.62%,5.40%,3.27M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-383.18%,-24.23%,-43.39%,67.18M,1.18,"40,474.20%",-157.11M,-254.84M,-254.98M,-4.49,,502.18M,8.66,30.98M,6.16,8.57,8.69,-227M,-137.13M,Value,02451,Healthcare,350,9,7,"Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing immunokinase inhibitors comprising vimseltinib (DCC-3014) that is in Phase 1b/2 clinical trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase 1b/2 clinical trial to treat metastatic solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, it is developing DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. The company serves in the United States and Europe. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.",Waltham,781 209 6400,MA,8,1609372800,1625097600,8,United States,http://www.deciphera.com,86400,8,200 Smith Street,785 830 2150,Biotechnology
